Gilead Shares Fall 1.5% to $147.83, Trades at 17.3 P/E Discount
Gilead Sciences closed at $147.83, down 1.46%, underperforming the S&P 500's 0.94% drop, while the stock has gained 5% over the past month versus a 2.62% Medical sector rise. Analysts project Q1 EPS of $1.86 (+2.8% yoy) on $6.86B revenue (+2.9%), with a forward P/E of 17.3 below peers.
1. Share Price Movement
Gilead Sciences closed the session at $147.83, a 1.46% drop from the prior day, underperforming the S&P 500 (-0.94%), Dow (-0.83%) and Nasdaq (-1.02%).
2. Monthly Performance
The stock has climbed 5% over the past month, outpacing the Medical sector's 2.62% gain and reversing the S&P 500's 1.3% decline over the same period.
3. Q1 Earnings Projections
Analysts forecast first-quarter earnings per share of $1.86, up 2.76% year-over-year, on revenue of $6.86 billion, representing a 2.93% increase from the prior-year quarter.
4. Valuation Metrics
Gilead trades at a forward P/E ratio of 17.33, below the industry average of 19.56, while its PEG ratio stands at 1.97 versus a sector average of 1.54.